UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 1, 2015
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S Employer
Identification No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
7.01 Regulation FD Disclosure
On
May 1, 2015, Cortex Pharmaceuticals, Inc. (the “Company”) announced that the Company’s Executive Chairman
and CEO, Dr. Arnold S. Lippa, Ph.D., will be presenting at the New York BIO 25th Anniversary Conference (the
“Conference”) at 10 on the Park @ Time Warner Center. Dr. Lippa is currently scheduled to present at 10:30 a.m.
Eastern Time on Monday, May 4, 2015. The slide presentation that the Company will be using at the Conference is attached as
Exhibit 99.1 and is being furnished and not filed pursuant to Item 7.01 of Form 8-K.
Item
8.01 Other Events
The information
provided in Item 7.01 is incorporated herein by reference. The press release announcing the Company’s participation in the
Conference is attached as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of
exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: May 1, 2015 |
CORTEX PHARMACEUTICALS,
INC. |
|
(Registrant) |
|
By: |
/s/
ARNOLD S. LIPPA |
|
|
Arnold S. Lippa
President and Chief Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
99.1 |
|
Slide Presentation* |
99.2 |
|
Press Release dated May 1, 2015* |
*Furnished
herewith.
Exhibit
99.1
Exhibit
99.2
Cortex
Pharmaceuticals, Inc. to Present at
NewYorkBIO
25th Anniversary Conference
Glen
Rock, N.J., May 1, 2015/Globe Newswire – Cortex Pharmaceuticals, Inc. (CORX) (“Cortex” or the “Company”),
a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces
that it will be presenting at the NewYorkBIO 25th Anniversary Conference (http://conference.newyorkbio.org). The conference
will take place on May 4 – 5, 2015 at 10 on the Park @ Time Warner Center.
The
Company’s Executive Chairman and CEO, Dr. Arnold S. Lippa, Ph.D., is currently scheduled to present at 10:30 a.m. Eastern
Time on Monday, May 4, 2015, in what is a referred to as a “Pitch & Partner Forum.” Dr. Lippa will present details
of Cortex’s initiatives with dronabinol for obstructive sleep apnea (Phase 2B), CX-1739 (oral) for drug-induced respiratory
depression and central sleep apnea (both Phase 2A), and CX-1942 (injectable) for drug-induced respiratory depression (preclinical),
as well as background data.
NewYorkBIO
is an organization that advocates for the New York life science industry, “helping to define the industry, protect its interests
and grow its opportunities.” The conference will have more than 660 attendees, 65% of which are Managers, Directors, C-level
or Executive Management, with one-third from outside New York State. In addition to the “Pitch & Partner Forums,”
there will be three major symposia, more than 24 panels and major keynote speakers.
A
copy of this press release and a copy of the slide presentation to be presented at the conference are being submitted as Exhibits
to a Current Report on Form 8-K and will also be available in the investors section of Cortex’s website (www.cortexpharm.com).
About
Cortex Pharmaceuticals, Inc.
Cortex
Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment
of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.
The
first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors.
Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory
depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy
in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects
of drugs such as propofol. The Company’s compounds belong to a new generation of ampakines that do not display the undesirable
side effects displayed by previous compounds.
The
second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in
a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B clinical study
is currently being conducted by the University of Illinois and is being funded by the National Institutes of Health.
Additional
information about Cortex and the matters discussed herein can be obtained on the Company’s website at www.cortexpharm.com
or in the Company’s filings on EDGAR at www.sec.gov.
Special
Note Regarding Forward-Looking Statements: Certain statements included or incorporated by reference in this news release,
including information as to the future financial or operating performance of the Company and its drug development programs, constitute
forward-looking statements. The words “believe,” “expect,” “anticipate,” “contemplate,”
“target,” “plan,” “intend,” “continue,” “budget,” “estimate,”
“may,” “schedule” and similar expressions identify forward-looking statements. Forward-looking statements
include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently
subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company’s
actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of,
the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations. Investors
are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned
not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Forward-looking statements are
made as of the date of this news release and the Company disclaims any intent or obligation to update publicly such forward-looking
statements, whether as a result of new information, future events or results or otherwise.
Company
Contact:
Jeff Margolis
Vice-President and Secretary
Telephone:
(917) 834-7206
E-mail: jmargolis@cortexpharm.com
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024